I think, Madam Chair, with great respect, CanSino was not at the heart of the Canadian strategy, by any means. It was a much more balanced approach. The task force, as Joanne and Mark indicated, recommended strongly for a diversified portfolio across both vaccine platforms and companies. At all times, a full-court press was put on all fronts. There was no effort made by anybody to privilege one company over another, and certainly not CanSino.
On February 18th, 2021. See this statement in context.